When A Cystoscopy Leads To a Heart Attack
Dr. Y, age 57, is an experienced general urologist who practices at a university hospital in the Northeast.
Print Issue: May 01, 2007
When to Use Intravesical Therapies
Bladder cancer is projected to be the fourth most common cancer diagnosed in 2007 and the eighth most common cause of cancer-specific death in men, according to the American Cancer Society. Approximately 70% of bladder tumors present as non-muscle invasive (NMI) disease and 10%-20% will progress to muscle invasion.
Hydronephrosis Prolongs Stone Clearance Time
In patients with solitary distal ureteral stones, hydronephrosis is associated with prolonged stone clearance following shock wave lithotripsy (SWL), but the degree of hydronephrosis caused by the stones does not affect overall SWL outcome.
Risk Factors for Post-TVT Voiding Problems Identified
Age and maximal peak flow rate before tension-free vaginal tape (TVT) placement are independent risk factors for postoperative voiding dysfunction, a French study found.
Higher Prostate Cancer Risk Found in BPH Drug Users
Men who take finasteride or alpha blockers for BPH are at higher risk of prostate cancer than non-users, investigators in Finland conclude.
Mitomycin C, BCG Comparable For High-Risk Bladder Cancer
A 10-year follow-up study of patients with high-risk bladder cancer shows that mitomycin C (MMC) and bacillus Calmette-Guérin (BCG) have similar effects on disease progression, need for subsequent treatment, and survival.
PCa Risk Not Lower in Men with Fluctuating PSA Level
Contrary to what is commonly thought, the risk of having a positive repeat prostate biopsy is no lower for men with a fluctuating PSA level than it is for those with a steady or steadily increasing PSA level.
PVP, TURP Outcomes Similar
Photoselective vaporization of the prostate (PVP) for BPH provides outcomes similar to those of transurethral resection of the prostate (TURP).
Alpha Blocker May Enhance Ureteral Stone Expulsion
Adding the alpha blocker doxazosin to standard treatment may help clear distal ureteral stones, according to researchers in Tashkent, Uzbekistan.
Sorafenib Benefit Unaffected by Prior Cytokine Therapy
Sorafenib treatment doubles progression-free survival in patients with advanced renal cell carcinoma, regardless of whether they have received prior cytokine therapy.
- Loading...
Loading...
Loading... 
Loading...